‘Tis the Season to Pretend GLP-1 Costs Are Sustainable

The best parts of writing a blog?

First, typing whatever you want and then watching marketing gently transform it into something fit for public consumption. Second, trying to squeeze a sprawling, emotional topic into 1,080 words and pretending that’s a reasonable constraint. Third—and perhaps the best part—picking a title that’s cheeky, clickable, and captures your exact vibe.

For this piece, the almost-but-not-quite titles were:

• Sleigh My Drug Spend: The GLP-1 Edition
• When Your Employees Want GLP-1s for Christmas and You Want a Budget for New Year’s

If I’m the only one having fun, feel free to sip your eggnog and move along: GLP-1 blogs are a dime a dozen. But this one comes with holiday cheer. You’re welcome.

In the spirit of giving, here’s the short version

• Should employers cover GLP-1s for weight loss? Maybe.
• How do we manage the cost? Intentionally.
• Should I personally be taking a GLP-1? Easy there, Reindeer.

Under the Wrapping Paper: What the Evidence Actually Says

Before diving into the questions, a little context. Several respected U.S. and international agencies evaluate medications for clinical impact and cost. Across their GLP-1 reviews, the themes are consistently clear:

• These work in addition to lifestyle modification. GLP-1s are clinically effective, though not all are created equal.
• The health value is generally worth the cost. Cost-effective, particularly with negotiated net pricing and long-term comorbidity reductions.
• We can’t afford them for everyone. Budget impact is the Grinch stealing financial joy.
• Utilization management (access criteria) is universally recommended.

Question 1: Should Employers Cover GLP-1s for Obesity?

If you’re a self-funded captive employer, you get to make this decision. Majority already cover GLP-1s for diabetes and other FDA-approved indications, but many remain cautious about obesity.

I’m not here to push you one way or another. I’m here to encourage an informed decision.

Reputable agencies consider GLP-1s cost-effective for weight loss. That makes sense: obesity is deeply intertwined with a whole sleighful of chronic conditions and high-cost claims.

Important distinction:

• Cost-effective = the health benefits justify the spend.
• Cost-saving = you spend less overall.

These are not the same thing. The trick isn’t whether GLP-1s work—they do. The trick is how to invest in them wisely so they’re financially sustainable.

Stocking-Stuffer Considerations

1. Your Population: What does your data show about obesity prevalence? Is this a benefit your employees are likely to use or expect?
2. Your Cost: How are you accessing these medications? Are you paying optimal rates or retail shelf pricing?
3. The Cost Analysis is Immature: Pricing, sourcing, and long-term outcomes are in motion, and today’s models are early and evolving. Consider whether you want to be Rudolph up front or follow once the path is a bit brighter

Question 2: How Do We Manage the Cost? Three Wise Cost Considerations

Your first reaction may be to panic. Totally fair. Deep breaths. Sip cocoa. Panicking has never solved a pharmacy trend.

However, these medications really do seem to defy our historical playbook. We’ve seen expensive therapies before—MS drugs, cancer immunotherapy, hemophilia care, Humira, Hep C cures—but none combine:

High Utilization + High Unit Cost + Chronic, Indefinite Use.

A holiday trifecta no CFO asked for.

Still, Christmas is not canceled. The sun will rise tomorrow. And markets adapt…eventually. It’s just a matter of whose dollar gets them there.

Think of GLP-1 expectations like a string of Christmas lights. They tangle easily if not handled thoughtfully.

Now, about those Wise Considerations…

1. Actually try lifestyle modification efforts first.

And no GLP-1 without muscle preservation and protein—just like no holiday season without a tree and lights. If you’re unwilling to invest in behavior change, it becomes difficult to justify this medication class.

2. Start slow and strategic with indications.

Begin with FDA-approved uses:

• Type 2 diabetes
• Cardiovascular risk reduction
• CKD risk reduction
• Osteoarthritis with obesity
• MASH with fibrosis

Use high-quality utilization management to ensure appropriate use—and check it twice. Then check it again. (Santa approves.)

3. Treat adherence and review as your North Star.

Health benefits require continued use. Real-world data shows fewer than ~36% of patients remain on GLP-1 therapy at 12 months. If adherence isn’t supported, you’re pouring money down the chimney.

Strategize around:

• side effects
• ongoing patient cost sharing
• access and affordability
• coaching and follow-up
• barriers to continuation

And set a calendar reminder to review your GLP-1 strategy annually using actual data—not headlines, fear, or vibes.

No one wants a January renewal that feels like coal in the stocking.

Question 3: Should You Take a GLP-1? A Reindeer Reality Check

Feeling tempted? Swept up in the cultural tide? Thinking:

“I don’t technically qualify, but I heard… I saw… my friend said…”

I love medications—it’s on my certificate—but let’s pause before injecting anything.

The Good News

Strong evidence is emerging for GLP-1 benefits in:

• Heart failure
• Diabetes prevention
• Additional kidney protection

And some very early (and needing much more time and data) signals in:

• Brain/mood effects
• Alcohol use disorder
• PCOS
• Addiction
• Organ protection
• Certain cancer-related pathways

Science is promising, but it’s not peppermint-flavored magic.

If you don’t fit an FDA-approved indication (for now):

• Try fruits and vegetables.
• Move your body—an absurd amount.
• Repeat daily.

A Captive Community Worth Joining

Yes, I work for a captive manager. And that’s exactly why I love these conversations.

Employers navigating GLP-1 strategy shouldn’t have to do it alone. In a captive community, you gain peers wrestling with the same questions:

• Are our utilization-management strategies working?
• What does real-world long-term data show?
• What partnerships or alternative solutions stretch dollars further?
• What’s our aggregate risk picture?
• How are stop-loss carriers viewing GLP-1 exposure heading into 2026 and beyond?

These aren’t intimidating questions. They’re smart, forward-looking ones. And you deserve a community where they can be explored honestly.

A Few Final Christmas Cookies of Wisdom

GLP-1s aren’t going anywhere. They’re powerful, complicated, and promising tools, and they require thoughtful strategy, clear criteria, and real-world data.

So, consider this an appetizer. Not enough words to touch microdosing, food noise, direct-to-consumer pricing, compounding, SDOH impacts on obesity, pharmacogenomics, long-term safety, and more.

GLP-1s: To Be Continued…

Nerds note: GLP-1 used as a general term for GLP-1 RAs and GLP-1/GIP RAs. References reviewed with cheer. Science is super cool.